tldrdailynews.com logo

FDA advisers recommend approval of Alzheimer's drug Lecanemab.

1 min read
Source: CNN
FDA advisers recommend approval of Alzheimer's drug Lecanemab.
Photo: CNN
TL;DR

An advisory panel for the US FDA voted unanimously that the Alzheimer’s drug lecanemab shows “clinical benefit” for the treatment of the disease, paving the way for the medication to be considered for full FDA approval. Lecanemab is one of the first dementia drugs that appears to slow the progression of cognitive decline. The drug is not a cure but works by binding to amyloid beta, a hallmark of Alzheimer’s disease. A decision from the FDA is expected by July 6.

Topics:businesshealth#alzheimers#clinical-benefit#fda#health#lecanemab#medication
Share this article
  1. FDA advisers vote that lecanemab shows benefit as an Alzheimer’s treatment  CNN
  2. FDA advisors endorse Alzheimer’s treatment Leqembi paving way for full approval this summer  CNBC
  3. Biogen Stock Halted as FDA Committee Considers Alzheimer's Drug  The Wall Street Journal
  4. Alzheimer's Drug Clears Major Hurdle Toward Full Approval  Medpage Today
  5. Pharmalittle: FDA panel to review Alzheimer's treatment; FDA advisers back approval of RSV drug for children  STAT

Want the full story? Read the original reporting

Read on CNN